The worldwide Genomic Cancer Testing Market stood at USD 18.47 billion in 2024, and is poised to reach USD 86.13 billion by 2034, recording a CAGR of 16.8% from 2025 through 2034.
Genomic Cancer Testing encompasses challenges.
Several factors contribute to this trajectory, including heightened requirement next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold marked shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Genomic Cancer Testing Market Snapshot
Chapter 4. Global Genomic Cancer Testing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Technology Estimates & Trend Analysis
5.1. By Technology, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Technology:
5.2.1. Next-Generation Sequencing (NGS)
5.2.2. Polymerase Chain Reaction (PCR)
5.2.3. Fluorescence In Situ Hybridization (FISH)
5.2.4. Microarray
5.2.5. Immunohistochemistry (IHC)
5.2.6. Other genomic testing technologies
Chapter 6. Market Segmentation 2: By Test Type Estimates & Trend Analysis
6.1. By Test Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Test Type:
6.2.1. Genomic Profiling Tests
6.2.2. Liquid Biopsy Tests
6.2.3. Companion Diagnostic Tests
6.2.4. Pharmacogenomic Tests
6.2.5. Hereditary Cancer Tests
6.2.6. Other specialized genomic tests
Chapter 7. Market Segmentation 3: By Cancer Type Estimates & Trend Analysis
7.1. By Cancer Type & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Cancer Type:
7.2.1. Breast Cancer
7.2.2. Lung Cancer
7.2.3. Colorectal Cancer
7.2.4. Prostate Cancer
7.2.5. Ovarian Cancer
7.2.6. Melanoma
7.2.7. Leukemia
7.2.8. Lymphoma
7.2.9. Other specific cancer types
Chapter 8. Market Segmentation 4: By End-User Estimates & Trend Analysis
8.1. By End-User & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-User:
8.2.1. Hospitals
8.2.2. Diagnostic Laboratories
8.2.3. Academic and Research Institutions
8.2.4. Cancer Centers
8.2.5. Other healthcare providers
Chapter 9. Market Segmentation 5: By Biomarker Type Estimates & Trend Analysis
9.1. By Biomarker Type & Market Share, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Biomarker Type:
9.2.1. Genetic Biomarkers
9.2.2. Protein Biomarkers
9.2.3. Molecular Biomarkers
9.2.4. Epigenetic Biomarkers
Chapter 10. Market Segmentation 6: By Service Provider Estimates & Trend Analysis
10.1. By Service Provider & Market Share, 2024 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Service Provider:
10.2.1. Diagnostic Laboratories
10.2.2. Biotechnology Companies
10.2.3. Pharmaceutical Companies
10.2.4. Contract Research Organizations (CROs)
Chapter 11. Market Segmentation 7: By Application Estimates & Trend Analysis
11.1. By Application & Market Share, 2024 & 2034
11.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
11.2.1. Targeted Therapy Selection
11.2.2. Disease Monitoring
11.2.3. Prognostic Testing
11.2.4. Companion Diagnostics
11.2.5. Risk Assessment
11.2.6. Pharmacogenomic Testing
Chapter 12. Market Segmentation 8: By Testing Setting Estimates & Trend Analysis
12.1. By Testing Setting & Market Share, 2024 & 2034
12.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Testing Setting:
12.2.1. In-House Testing
12.2.2. Outsourced Testing
Chapter 13. Genomic Cancer Testing Market Segmentation 9: Regional Estimates & Trend Analysis
13.1. North America
13.1.1. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Technology, 2021-2034
13.1.2. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Test Type, 2021-2034
13.1.3. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Cancer Type, 2021-2034
13.1.4. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By End-User, 2021-2034
13.1.5. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Biomarker Type, 2021-2034
13.1.6. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Service Provider, 2021-2034
13.1.7. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Application, 2021-2034
13.1.8. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Testing Setting, 2021-2034
13.1.9. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts by country, 2021-2034
13.2. Europe
13.2.1. Europe Genomic Cancer Testing Market revenue in US$ Million By Technology, 2021-2034
13.2.2. Europe Genomic Cancer Testing Market revenue in US$ Million By Test Type, 2021-2034
13.2.3. Europe Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, 2021-2034
13.2.4. Europe Genomic Cancer Testing Market revenue in US$ Million By End-User, 2021-2034
13.2.5. Europe Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, 2021-2034
13.2.6. Europe Genomic Cancer Testing Market revenue in US$ Million By Service Provider, 2021-2034
13.2.7. Europe Genomic Cancer Testing Market revenue in US$ Million By Application, 2021-2034
13.2.8. Europe Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, 2021-2034
13.2.9. Europe Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
13.3. Asia Pacific
13.3.1. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Technology, 2021-2034
13.3.2. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Test Type, 2021-2034
13.3.3. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, 2021-2034
13.3.4. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By End-User, 2021-2034
13.3.5. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, 2021-2034
13.3.6. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Service Provider, 2021-2034
13.3.7. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Application, 2021-2034
13.3.8. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, 2021-2034
13.3.9. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
13.4. Latin America
13.4.1. Latin America Genomic Cancer Testing Market revenue in US$ Million By Technology, (US$ Million) 2021-2034
13.4.2. Latin America Genomic Cancer Testing Market revenue in US$ Million By Test Type, (US$ Million) 2021-2034
13.4.3. Latin America Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, (US$ Million) 2021-2034
13.4.4. Latin America Genomic Cancer Testing Market revenue in US$ Million By End-User, (US$ Million) 2021-2034
13.4.5. Latin America Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, (US$ Million) 2021-2034
13.4.6. Latin America Genomic Cancer Testing Market revenue in US$ Million By Service Provider, (US$ Million) 2021-2034
13.4.7. Latin America Genomic Cancer Testing Market revenue in US$ Million By Application, (US$ Million) 2021-2034
13.4.8. Latin America Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, (US$ Million) 2021-2034
13.4.9. Latin America Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
13.5. Middle East & Africa
13.5.1. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Technology, (US$ Million) 2021-2034
13.5.2. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Test Type, (US$ Million) 2021-2034
13.5.3. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, (US$ Million) 2021-2034
13.5.4. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By End-User, (US$ Million) 2021-2034
13.5.5. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, (US$ Million) 2021-2034
13.5.6. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Service Provider, (US$ Million) 2021-2034
13.5.7. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Application, (US$ Million) 2021-2034
13.5.8. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, (US$ Million) 2021-2034
13.5.9. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
Chapter 14. Competitive Landscape
14.1. Major Mergers and Acquisitions/Strategic Alliances
14.2. Company Profiles
14.2.1. Illumina, Inc.,
14.2.2. Thermo Fisher Scientific, Inc.,
14.2.3. Qiagen N.V.,
14.2.4. F. Hoffmann-La Roche Ltd.,
14.2.5. Foundation Medicine, Inc. (Roche),
14.2.6. Invitae Corporation,
14.2.7. NeoGenomics Laboratories, Inc.,
14.2.8. Myriad Genetics, Inc.,
14.2.9. Genomic Health, Inc. (Exact Sciences Corporation),
14.2.10. Caris Life Sciences,
14.2.11. ArcherDX, Inc. (Invitae Corporation),
14.2.12. Guardant Health, Inc.,
14.2.13. Personal Genome Diagnostics Inc.,
14.2.14. Biocept, Inc.,
14.2.15. Tempus Labs, Inc.
14.2.16. Danaher
14.2.17. PerkinElmer
14.2.18. Agilent Technologies, Inc
14.2.19. Quest Diagnostics
14.2.20. Luminex Corporation
14.2.21. Others